News

The company is seeking marketing approval for ferumoxytol as an intravenous treatment of iron deficiency anemia in patients with CKD, including dialysis dependent and non-dialysis dependent patients. The

The warrants have an exercise price of $12.50 per share and a term of 3 years.

The Treanda NDA for relapsed indolent NHL is supported by three studies in patients with NHL, including two single-agent studies and one in combination with rituximab. In these

According to USAMRIID scientists, animal studies to test the efficacy of these nanoviricides drug candidates against Ebola infection will be undertaken shortly. It is hoped that success against

The collaboration will evaluate Celera’s numerous genetic findings in liver diseases, including the Cirrhosis Risk Score, in the Geisinger bank of more than 600 liver tissue and blood

The biomarker study will enroll approximately 12 patients with stable schizophrenia who are receiving atypical antipsychotic therapy. Subjects will be randomized to receive MEM 3454 and placebo in

Accordingly, CytoPharm, the company’s partner in Taiwan, will fund and conduct a clinical trial of 144 chronic hepatitis C patients in Taiwan. The patients will receive one of

The Zegerid products were developed by Santarus and are the first and only immediate-release oral proton pump inhibitors (PPIs) commercialized in the US. Zegerid (omeprazole/sodium bicarbonate) capsules and

Attental has been proven in a randomized, double-blind, placebo controlled clinical trial to better overall motor performance and improve reading and spelling in children. The clinical trial demonstrated